| scholarly article | Q13442814 |
| P356 | DOI | 10.1001/JAMA.2015.3868 |
| P698 | PubMed publication ID | 25942724 |
| P50 | author | Christophe Hézode | Q40353472 |
| Fred Poordad | Q47412568 | ||
| Gregory J Dore | Q90411646 | ||
| P2093 | author name string | Albert Tran | |
| Fiona McPhee | |||
| Rong Yang | |||
| Andrew J Muir | |||
| Jacob Lalezari | |||
| Paul J Pockros | |||
| E Scott Swenson | |||
| Nancy Reau | |||
| Alexander J Thompson | |||
| Philip D Yin | |||
| Alnoor Ramji | |||
| Christophe Hézode | |||
| Eric A Hughes | |||
| Wayne Ghesquiere | |||
| Paul Kwo | |||
| Bradley Freilich | |||
| John Vierling | |||
| James Cooper | |||
| Katherine Stuart | |||
| Robert Herring | |||
| Gregory Everson | |||
| Aasim Sheikh | |||
| Joseph Yozviak | |||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | liver cirrhosis | Q147778 |
| Hepatitis C virus | Q708693 | ||
| daclatasvir | Q5207712 | ||
| P304 | page(s) | 1736-1744 | |
| P577 | publication date | 2015-05-01 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis | |
| P478 | volume | 313 |
| Q28068712 | A Review of Daclatasvir Drug-Drug Interactions |
| Q40745549 | A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin |
| Q26770036 | Advances in hepatitis C therapy: What is the current state - what come's next? |
| Q27755387 | Approved Antiviral Drugs over the Past 50 Years |
| Q47593083 | Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C. |
| Q38594613 | Asunaprevir (BMS-650032) for the treatment of hepatitis C virus |
| Q26745582 | Conceptual framework for outcomes research studies of hepatitis C: an analytical review |
| Q39151677 | Current therapy for chronic hepatitis C: The role of direct-acting antivirals |
| Q40949225 | Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients |
| Q50058053 | Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety |
| Q38628237 | Daclatasvir for the treatment of chronic hepatitis C. |
| Q38398290 | Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis. |
| Q36724391 | Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1 |
| Q28077287 | Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis |
| Q38626467 | Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection. |
| Q38859479 | Daclatasvir/Asunaprevir/Beclabuvir (DCV-TRIO), All-Oral, Fixed-Dose Combination for Patients With Chronic HCV Genotype 1. |
| Q40583906 | Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection |
| Q40638362 | Daclatasvir/peginterferon lambda-1a/ribavirin in patients with chronic HCV infection and haemophilia who are treatment naïve or prior relapsers to peginterferon alfa-2a/ribavirin |
| Q26767329 | Direct anti-HCV agents |
| Q57389418 | Direct-acting antivirals for chronic hepatitis C |
| Q34557595 | Direct-acting antivirals for chronic hepatitis C. |
| Q37615174 | Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment. |
| Q47278098 | Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects |
| Q39015799 | Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview |
| Q37097611 | Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection |
| Q37738808 | Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study |
| Q38837174 | Efficacy of Interferon-Free Therapies for Chronic Hepatitis C: A Systematic Review of All Randomized Clinical Trials. |
| Q57038984 | Engineered small molecule control of influenza A virus replication |
| Q91154983 | Exposure-Response Analysis for Efficacy of Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV-Infected Patients |
| Q92405707 | Forced Oxidative Degradation Pathways of the Imidazole Moiety of Daclatasvir |
| Q40867184 | HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels |
| Q30378509 | Hepatitis C treatment: where are we now? |
| Q35907984 | High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms |
| Q26782017 | Impact of new treatment options for hepatitis C virus infection in liver transplantation |
| Q59354172 | Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era |
| Q26746563 | Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection |
| Q28087400 | Interferon-free combination therapies for the treatment of hepatitis C: current insights |
| Q31051529 | Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development. |
| Q40458975 | Is stronger better in curing hepatitis C virus infection? |
| Q41931578 | Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens |
| Q26783874 | Management before hepatectomy for hepatocellular carcinoma with cirrhosis |
| Q38702156 | Management of hepatitis C patients with decompensated liver disease. |
| Q36497834 | Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease. |
| Q39031350 | NS5A inhibitors for the treatment of hepatitis C infection |
| Q38875280 | New Direct-Acting Antiviral Therapies for Treatment of Chronic Hepatitis C Virus Infection |
| Q26773271 | New approaches in the treatment of hepatitis C |
| Q40899794 | New hepatitis C therapies for special patient populations |
| Q57413429 | Oral direct-acting antivirals and the incidence or recurrence of hepatocellular carcinoma: a systematic review and meta-analysis |
| Q26751452 | Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment |
| Q90984286 | Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV-Infected Subjects |
| Q57164745 | Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection |
| Q39203624 | Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation? |
| Q40341184 | Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection |
| Q41041935 | Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. |
| Q40587241 | Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir |
| Q38503778 | Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection |
| Q26775002 | Ribavirin: Past, present and future |
| Q90633566 | Safety Exposure-Response Analysis for Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV-Infected Subjects |
| Q38903835 | Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis. |
| Q40413372 | Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study). |
| Q91768250 | Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C |
| Q39038238 | Small-molecule inhibitors of hepatitis C virus (HCV) non-structural protein 5A (NS5A): a patent review (2010-2015). |
| Q26777086 | Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomes |
| Q26768128 | Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1 |
| Q39034453 | The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir |
| Q38634221 | The safety of daclatasvir for the treatment of hepatitis C. |
| Q28070260 | Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis |
| Q42986984 | Treatment of hepatitis C virus genotype 1-infected patients: mission accomplished? |
Search more.